130 related articles for article (PubMed ID: 26079332)
1. What is the Optimal Way to Select Candidates for Active Surveillance of Prostate Cancer?
Dall'Era M; Carroll P
J Urol; 2015 Sep; 194(3):615-6. PubMed ID: 26079332
[No Abstract] [Full Text] [Related]
2. [Active surveillance of prostate cancer].
Ploussard G; Hennequin C; Rozet F
Cancer Radiother; 2017 Oct; 21(6-7):437-441. PubMed ID: 28847461
[TBL] [Abstract][Full Text] [Related]
3. Population based study of use and determinants of active surveillance and watchful waiting for low and intermediate risk prostate cancer.
Loeb S; Berglund A; Stattin P
J Urol; 2013 Nov; 190(5):1742-9. PubMed ID: 23727309
[TBL] [Abstract][Full Text] [Related]
4. [Criticisms to patient selection in active surveillance in prostate cancer].
Gomez Veiga F; Portela Pereira P; Vazquez-Martul Pazos D; Pertega Diaz S; Martinez Breijo S; Mendez Diaz C; Rodríguez E
Arch Esp Urol; 2014 Jun; 67(5):495-508. PubMed ID: 24914849
[TBL] [Abstract][Full Text] [Related]
5. Active surveillance preferred for low-risk prostate cancer.
Bagcchi S
Lancet Oncol; 2015 Aug; 16(8):e384. PubMed ID: 26190749
[No Abstract] [Full Text] [Related]
6. Low-risk and very-low-risk prostate cancer: is there a role for focal therapy in the era of active surveillance? Yes, the two approaches complement each other.
Klotz L; Polascik TJ
Oncology (Williston Park); 2014 Nov; 28(11):950-C3. PubMed ID: 25741545
[No Abstract] [Full Text] [Related]
7. Further support for active surveillance in the management of low-volume, low-grade prostate cancer.
Albertsen P
Eur Urol; 2010 Dec; 58(6):836-7. PubMed ID: 20851512
[No Abstract] [Full Text] [Related]
8. Low-risk and very-low-risk prostate cancer: is there a role for focal therapy in the era of active surveillance? No, focal therapy provides a false sense of security and no proven benefits.
Nelson JB
Oncology (Williston Park); 2014 Nov; 28(11):951-C3. PubMed ID: 25741546
[No Abstract] [Full Text] [Related]
9. Spatial distribution of positive cores improves the selection of patients with low-risk prostate cancer as candidates for active surveillance.
Abdollah F; Suardi N; Capitanio U; Gallina A; Sun M; Villa L; Scattoni V; Bianchi M; Tutolo M; Fossati N; Karakiewicz P; Rigatti P; Montorsi F; Briganti A
BJU Int; 2013 Aug; 112(4):E234-42. PubMed ID: 23746297
[TBL] [Abstract][Full Text] [Related]
10. Active Surveillance is an Appropriate Management Strategy for a Proportion of Men Diagnosed with Prostate Cancer by Prostate Specific Antigen Testing.
Overholser S; Nielsen M; Torkko K; Cwilka D; Weaver B; Shi X; Leach RJ; Hernandez J; Huang T; Thompson IM; Thompson IM
J Urol; 2015 Sep; 194(3):680-4. PubMed ID: 25636657
[TBL] [Abstract][Full Text] [Related]
11. The ongoing need for improved risk stratification and monitoring for those on active surveillance for early stage prostate cancer.
Welty CJ; Carroll PR
Eur Urol; 2014 Jun; 65(6):1032-3. PubMed ID: 24636678
[No Abstract] [Full Text] [Related]
12. Management of localised prostate cancer: watchful waiting, surgery or radiation therapy, depending on the natural course, which is often relatively slow.
Prescrire Int; 2012 Oct; 21(131):242-8. PubMed ID: 23185849
[TBL] [Abstract][Full Text] [Related]
13. The economics of active surveillance for prostate cancer.
Dall'Era MA
Curr Opin Urol; 2013 May; 23(3):278-82. PubMed ID: 23449496
[TBL] [Abstract][Full Text] [Related]
14. [Editorial. Monographic: Active surveillance in prostate cancer].
Rubio-Briones J; Narbón ES
Arch Esp Urol; 2014 Jun; 67(5):369-71. PubMed ID: 25039088
[No Abstract] [Full Text] [Related]
15. Tumor lesion diameter on diffusion weighted magnetic resonance imaging could help predict insignificant prostate cancer in patients eligible for active surveillance: preliminary analysis.
Lee DH; Koo KC; Lee SH; Rha KH; Choi YD; Hong SJ; Chung BH
J Urol; 2013 Oct; 190(4):1213-7. PubMed ID: 23727188
[TBL] [Abstract][Full Text] [Related]
16. MRI and surveillance.
Ouzzane A; Puech P; Villers A
Curr Opin Urol; 2012 May; 22(3):231-6. PubMed ID: 22388665
[TBL] [Abstract][Full Text] [Related]
17. Role of multiparametric 3.0-Tesla magnetic resonance imaging in patients with prostate cancer eligible for active surveillance.
Park BH; Jeon HG; Choo SH; Jeong BC; Seo SI; Jeon SS; Choi HY; Lee HM
BJU Int; 2014 Jun; 113(6):864-70. PubMed ID: 24053308
[TBL] [Abstract][Full Text] [Related]
18. Selecting men diagnosed with prostate cancer for active surveillance using a risk calculator: a prospective impact study.
van Vugt HA; Roobol MJ; van der Poel HG; van Muilekom EH; Busstra M; Kil P; Oomens EH; Leliveld A; Bangma CH; Korfage I; Steyerberg EW
BJU Int; 2012 Jul; 110(2):180-7. PubMed ID: 22112199
[TBL] [Abstract][Full Text] [Related]
19. Expanded criteria to identify men eligible for active surveillance of low risk prostate cancer at Johns Hopkins: a preliminary analysis.
Reese AC; Landis P; Han M; Epstein JI; Carter HB
J Urol; 2013 Dec; 190(6):2033-8. PubMed ID: 23680308
[TBL] [Abstract][Full Text] [Related]
20. Multidisciplinary care and pursuit of active surveillance in low-risk prostate cancer.
Aizer AA; Paly JJ; Zietman AL; Nguyen PL; Beard CJ; Rao SK; Kaplan ID; Niemierko A; Hirsch MS; Wu CL; Olumi AF; Michaelson MD; D'Amico AV; Efstathiou JA
J Clin Oncol; 2012 Sep; 30(25):3071-6. PubMed ID: 22851571
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
